tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Humacyte announces publication of outcomes for patients treated with Symvess

Humacyte (HUMA) announced publication of outcomes for patients with hospital-acquired vascular complications treated with Symvess in the Journal of Vascular Surgery. The publication, titled “Bioengineered Human Blood Vessels to Treat Hospital-Acquired Vascular Complications,” reported that “Symvess was observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection in 12 patients with hospital-acquired iatrogenic injuries or complications of vascular surgical procedures.” The publication describes the outcomes of 12 patients with hospital-acquired iatrogenic injuries or complications of vascular surgical procedures. The 12 patients were a subgroup from Humacyte’s V005 pivotal Phase 2/3 clinical study conducted in the U.S. and Israel, and the results have not been published previously. The 12 patients required arterial repair or replacement due to damage from vascular interventions to treat peripheral artery disease, arterial excisions during tumor resections, steal syndrome, and injury during orthopedic surgery. At end of follow up 11 of 12 of patients retained secondary patency. None of the patients suffered an amputation, and there were zero confirmed infections of the conduit.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1